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Background -The acquisition of Pseudomonas cepacia in patients with cystic fibrosis is associated with increasing deterioration in lung function and more frequent hospital admissions. Pseudomonas cepacia is usually resistant to several antibiotics in vitro, but the response of patients colonised with the organism has not been extensively studied in vivo. Methods -A three month prospective study was performed to investigate the response of 14 Ps cepacia positive patients and 10 Ps cepacia negative patients to a two week course of intravenous antibiotics. All those who were Ps cepacia negative and six of the 14 Ps cepacia positive patients had Ps aeruginosa in their sputum which was sensitive to the prescribed therapy. The inflammatory markers Creactive protein, white blood cell count, serum lactoferrin, neutrophil elastase/aeantitrypsin complex, and tumour necrosis factor alpha were measured at the start and end of each antibiotic course. Results -The median (range) % improvement in baseline FEV, and FVC following treatment in the group as a whole was 15-2% (-23-5% to 156-3%) and 23-9% (-36-8% to 232-7%) respectively. There was no statistical difference in improvement in lung function, body weight, or inflammatory markers between individuals who were Ps cepacia positive and those who were Ps cepacia negative.
Conclusions -Patients who are Ps cepacia positive appear to respond as well to intravenous antibiotics as those who are Ps cepacia negative, despite having lower lung function and a bacterium in their sputum which is resistant in vitro to the antibiotics used.
(Thorax 1994;49:803-807)
In the UK the incidence and prevalence of Pseudomonas cepacia among patients with cystic fibrosis has significantly increased over the past few years.'-3 This can partly be explained by improvement in microbiological isolation techniques and by an increase in both social and hospital contacts among patients with cystic fibrosis.2 Despite the increased evidence for patient to patient transmission, it remains unclear whether Ps cepacia is a cause of, or marker of, disease severity.
In a small proportion of patients with Ps cepacia rapid and unexpected lung deterioration develops despite intensive antibiotic treatment. The isolation of Ps cepacia from blood cultures accompanied by clinical evidence of systemic sepsis provides evidence of a possible pathogenic role for this organism. 145 In most patients, however, a gradual decline in lung function occurs following the isolation of the organism.6 Pseudomonas cepacia is resistant to most antipseudomonal antibiotics in vitro.7 Our clinical impression is nevertheless that patients respond clinically to these antibiotics. Markers such as serum levels of neutrophil elastase/ot,-antitrypsin complex, lactoferrin, tumour necrosis factor alpha (TNFca), C-reactive protein, and white blood cell count have been shown previously to reflect the inflammatory process in patients with cystic fibrosis and are reduced following effective antipseudomonal treatment in patients colonised with Ps aeruginosa.8'0 It is not known, however, whether similar changes are seen after treatment in patients colonised with Ps cepacia. We have therefore prospectively studied the effectiveness of intravenous antibiotic therapy in a group of adult patients with cystic fibrosis, with and without Ps cepacia, measuring treatment response as change in inflammatory markers, lung function, and body weight.
Methods

STUDY DESIGN
This was a prospective study which included all patients who required two weeks of intravenous antibiotics for infective exacerbations of cystic fibrosis over a three month period at Nottingham City Hospital. Patients were assessed both before and at the end of the two week course of antibiotics with measurements of body weight, lung functions, and venous blood samples for measurements of inflammatory markers.
PATIENTS
Twenty four adult patients were studied, 10 of whom were colonised with Ps aeruginosa without Ps cepacia (Ps cepacia negative) and 14 of whom were colonised with Ps cepacia, with or without Ps aeruginosa (Ps cepacia positive). Clinical details are outlined in table 1. All patients had been chronically infected with Ps aeruginosa for more than two years. Of the patients who were Ps cepacia positive, this bacterium had been isolated from one patient three weeks before antibiotic therapy while the remaining 13 had repeatedly been positive for All patients who were Ps cepacia negative The results before and after treatment for the combined group are outlined in table 3. There was a significant fall in white blood cell count and serum levels of C-reactive protein, lactoferrin and acx-antitrypsin following treatment for the combined group. No differences were detected in the parameters studied between patients who were Ps cepacia positive and those who were Ps cepacia negative or between the two Ps cepacia subgroups (six Ps aeruginosa positive, six Ps aeruginosa negative). No significant difference was seen in the pretreatment, post-treatment, or in the change in any of the measured parameters. The median changes following treatment in the two groups are outlined in table 4. preferentially at 30°C. It is also possible that a heavy growth of Ps cepacia may inhibit the recognition of other organisms such as Staph aureus and Haemophilus. Whilst this is a possibility it would not explain the results of treatment directed towards Ps aeruginosa in our study. An alternative explanation is that the response in both patient groups is due solely to effective physiotherapy which is causing improvement by enhancing sputum expectoration and reducing the inflammatory stimulus, thus reducing levels of inflammatory markers. This latter possibility would seem unlikely as previous studies have shown that intravenous antibiotics alone are more effective than physiotherapy alone at reducing Ps aeruginosa counts in sputum.20 Antibiotics are also known to have other effects which may modify the response to infection including the release of endotoxin and the inhibition of the cytokine cascade. 26 The possible immunomodulatory effect combined with some in vivo antibacterial activity, physiotherapy, and nutritional support may explain the clinical improvement. Consequently, beneficial effects might be explained despite persistence of the organism. Lastly, we considered whether the response to treatment in patients colonised with Ps cepacia may reflect treatment of Ps aeruginosa rather than Ps cepacia. For this reason we have compared the two subgroups of patients who were Ps cepacia positive (with and without Ps aeruginosa) and have found no differences in either lung function or inflammatory markers between patients colonised with Ps aeruginosa and Ps cepacia and those colonised with Ps cepacia alone. This suggests that treatment was as effective when only Ps cepacia was present. Alternatively, the clinical response to antibiotic treatment among patients who appeared to be colonised by Ps cepacia alone may simply reflect the treatment of underlying Ps aeruginosa as the inability to isolate this organism from the sputum does not exclude its presence within the lower respiratory tract.
The fact that we found that patients who were Ps cepacia positive responded well to antibiotics suggests that the reason for the greater decline in their lung function in some studies may be the result of lung damage occurring between antibiotic courses.6 It is interesting that our patients who were Ps cepacia positive required more courses of intravenous antibiotics over the previous 12 months than those patients who were Ps cepacia negative.
We conclude, therefore, that antibiotic treatment of patients who are Ps cepacia positive is often effective in vivo despite the multiresistant nature of this organism in vitro. Further work is required to determine the relation between in vitro sensitivity results and the response in vivo and the pattern of inflammatory response over a prolonged period in patients who are Ps cepacia positive. From a practical point of view antibiotics should not be withheld from patients because of in vitro resistant patterns.
